Jeffrey Cates, DO
Psychiatry · Tulsa, OKNPI 1760543714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 38.5% of the total. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- Indivior Inc.$848
- Axsome Therapeutics, Inc.$555
- Neurocrine Biosciences, Inc.$389
- plus $2K from 10 others
Across 75 payments — averaging $495.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$37K
What the payments were for
- Food & beverage$11,04499%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 149 | $4,281 |
| Otsuka America Pharmaceutical, Inc. | 67 | $1,502 |
| Alkermes, Inc. | 71 | $1,393 |
| Indivior Inc. | 51 | $848 |
| Axsome Therapeutics, Inc. | 18 | $555 |
| Neurocrine Biosciences, Inc. | 18 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $379 |
| AbbVie | 10 | $369 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $333 |
| Teva Pharmaceuticals USA, Inc. | 17 | $324 |
| Sunovion Pharmaceuticals Inc. | 22 | $271 |
| Lundbeck LLC | 11 | $195 |
| Vanda Pharmaceuticals Inc. | 6 | $102 |
| Braeburn Inc. | 3 | $84 |
| Noven Therapeutics, LLC | 3 | $53 |
| Corium, LLC | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$1,295
- INVEGA TRINZA$909
- SPRAVATO$633
- ARISTADA$497
- REXULTI$491
- LYBALVI$403
- TRINTELLIX$328
- VRAYLAR$218
- LATUDA$125
- ARISTADA INITIO$124
- Auvelity$118
How this compares
$11,111 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 264 | $817,330 |
| Abilify MaintenaAripiprazole | 110 | $299,357 |
| Invega TrinzaPaliperidone Palmitate | 39 | $297,120 |
| IngrezzaValbenazine Tosylate | 42 | $228,584 |
| AristadaAripiprazole Lauroxil | 25 | $85,742 |
| AustedoDeutetrabenazine | 27 | $74,456 |
| RexultiBrexpiprazole | 34 | $48,408 |
| CaplytaLumateperone Tosylate | 22 | $36,161 |
| PerserisRisperidone | 12 | $28,888 |
| VraylarCariprazine Hcl | 20 | $28,316 |
| Clozapine | 94 | $10,219 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,268 |
| Ziprasidone Hcl | 72 | $8,355 |
| Chlorpromazine Hcl | 26 | $7,887 |
| Duloxetine Hcl | 310 | $6,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $4,281 | $1,114,450303 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,502 | $347,765144 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $389 | $228,58442 claims |
| Alkermes, Inc.Aristada | $1,393 | $85,74225 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $324 | $74,45627 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $333 | $36,16122 claims |
| Indivior Inc.Perseris | $848 | $28,88812 claims |
| AbbVieVraylar | $369 | $28,31620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $379 | $9,26817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Tulsa
- Sarah LandTulsa$287K
- Bradley McClureTulsa$15K
- Katrina CraderTulsa$15K
- Kaitlin CoresTulsa$10K
- Charles van TuylTulsa$9K
- Michael DubriwnyTulsa$8K
- Martin PaulusTulsa$7K
- Joe SpeerTulsa$7K
- Kari YoumanTulsa$5K
- Stevan LahrTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.